Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275930 | 1.00 | MAPT (0.47) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL880006 | 0.93 | PPM1B (0.46) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL5520720 | 0.87 | MAPT (0.46) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL1297212 | 0.86 | MAPT (0.51) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2341968 | 0.86 | MAPT (0.51) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2345801 | 0.86 | MAPT (0.51) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2341343 | 0.86 | MAPT (0.51) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2341347 | 0.86 | MAPT (0.51) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL11238956 | 0.85 | PPM1B (0.36) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL10190327 | 0.85 | GAA (0.45) | MAPTALDH1A1PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996189-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2012-09-26 | — | — | EP | disclosed |
| US-20110207777-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | TELECOM IP LIMITED | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207777-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | MAPT 603/4885ALDH1A1 308/4885PPM1B 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.